Eagle Asset Management Inc. lessened its stake in shares of Amedisys Inc (NASDAQ:AMED) by 0.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 289,952 shares of the health services provider’s stock after selling 1,290 shares during the quarter. Eagle Asset Management Inc.’s holdings in Amedisys were worth $37,986,000 as of its most recent SEC filing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Several other large investors also recently modified their holdings of AMED. Price T Rowe Associates Inc. MD lifted its position in shares of Amedisys by 286.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,349,405 shares of the health services provider’s stock worth $163,831,000 after buying an additional 999,892 shares during the last quarter. William Blair Investment Management LLC lifted its position in shares of Amedisys by 937.5% during the 2nd quarter. William Blair Investment Management LLC now owns 988,533 shares of the health services provider’s stock worth $120,018,000 after buying an additional 893,253 shares during the last quarter. Riverbridge Partners LLC purchased a new stake in shares of Amedisys during the 2nd quarter worth approximately $80,465,000. Nuveen Asset Management LLC lifted its position in shares of Amedisys by 2,107.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 261,108 shares of the health services provider’s stock worth $31,702,000 after buying an additional 249,280 shares during the last quarter. Finally, Carillon Tower Advisers Inc. purchased a new stake in shares of Amedisys during the 2nd quarter worth approximately $23,250,000. Institutional investors and hedge funds own 88.11% of the company’s stock.
AMED has been the subject of several recent analyst reports. Stephens restated an “equal weight” rating and set a $145.00 price objective on shares of Amedisys in a research report on Tuesday, October 22nd. Robert W. Baird upgraded shares of Amedisys from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $140.00 to $160.00 in a research report on Friday, November 1st. BidaskClub upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 26th. Barclays boosted their price objective on shares of Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Monday, August 5th. Finally, Raymond James boosted their price objective on shares of Amedisys from $140.00 to $144.00 and gave the stock an “outperform” rating in a research report on Monday, July 15th. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $145.36.
In related news, CFO Scott G. Ginn sold 7,690 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $145.17, for a total value of $1,116,357.30. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Christopher Gerard sold 350 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $134.79, for a total transaction of $47,176.50. Following the completion of the sale, the chief operating officer now directly owns 25,381 shares in the company, valued at $3,421,104.99. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,740 shares of company stock worth $1,395,053. 2.90% of the stock is owned by corporate insiders.
AMED stock opened at $149.25 on Friday. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 41.12, a price-to-earnings-growth ratio of 2.03 and a beta of 1.38. Amedisys Inc has a 12 month low of $103.76 and a 12 month high of $154.14. The company has a fifty day moving average price of $133.62 and a 200 day moving average price of $126.38. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.95 and a quick ratio of 0.95.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Tuesday, October 29th. The health services provider reported $1.15 EPS for the quarter, beating the Zacks’ consensus estimate of $0.90 by $0.25. The firm had revenue of $494.63 million for the quarter, compared to analysts’ expectations of $494.14 million. Amedisys had a net margin of 6.70% and a return on equity of 26.53%. The firm’s revenue was up 18.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.95 EPS. As a group, analysts anticipate that Amedisys Inc will post 4.39 earnings per share for the current year.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).